Outlook Therapeutics, Inc. (OTLK) has 59 open-market insider trades by 12 insiders since 2018. Over the last six months insiders net bought $7.9M. The most active filer is Kurt J. Hilzinger, Director.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Ghiath M. Sukhtian | Dir10% Owner | — | 3 | $27.5M | 2026-08-12 |
| GMS Ventures & Investments | Dir10% Owner | — | 1 | $8.4M | 2022-04-21 |
| Syntone Ventures LLC | 10% Owner | — | 2 | $5.0M | 2024-04-15 |
| Kurt J. Hilzinger | Dir | — | 17 | $1.4M | 2026-05-26 |
| Jeff Evanson | CCO | — | 6 | $1.0M | 2024-03-07 |
| Terry Dagnon | COO | — | 6 | $848K | 2023-04-20 |
| Faisal Ghiath Sukhtian | Dir | — | 6 | $239K | 2026-07-29 |
| Yezan Munther Haddadin | Dir | — | 7 | $144K | 2026-06-02 |
| Lawrence A. Kenyon | CFO | — | 4 | $72K | 2026-08-14 |
| C. Russell Trenary III | Pres | — | 3 | $70K | 2022-06-21 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Ghiath M. Sukhtian | Director & 10% Owner | Buy | $2.5M | 2026-08-12 |
| Faisal Ghiath Sukhtian | Director | Buy | $100K | 2026-07-29 |
| Yezan Munther Haddadin | Director | Buy | $24K | 2026-06-02 |
| Ghiath M. Sukhtian | Director & 10% Owner | Buy | $5.0M | 2026-05-28 |
| Faisal Ghiath Sukhtian | Director | Buy | $50K | 2026-05-27 |
| Randy H. Thurman | Director | Buy | $2K |
Companies that share insiders with OTLK, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| 2026-05-26 |
| Kurt J. Hilzinger | Director | Buy | $177K | 2026-05-26 |
| Yezan Munther Haddadin | Director | Buy | $15K | 2026-05-26 |
| Lawrence A. Kenyon | CFO | Buy | $28K | 2024-09-26 |
| Yezan Munther Haddadin | Director | Buy | $22K | 2024-03-28 |
| Jeff Evanson | CHIEF COMMERCIAL OFFICER | Buy | $26K | 2024-03-07 |
| Terry Dagnon | COO | Sell | $593K | 2023-04-20 |
| Jeff Evanson | CCO | Sell | $296K | 2023-01-20 |
| Jeff Evanson | CCO | Sell | $330K | 2023-01-17 |
| Faisal Ghiath Sukhtian | Director | Buy | $39K | 2022-10-07 |